For millions of Americans suffering from unexplained digestive issues, the journey to relief has long been frustrating and uncertain. Years can pass with patients cycling through elimination diets, keeping food journals, and undergoing inconclusive tests, all while their symptoms persist and their quality of life deteriorates. Now, a revolutionary diagnostic approach is changing that narrative, offering precise answers in a single procedure.

The CellTolerance^® Test, powered by Cellvizio^® technology, represents a paradigm shift in how physicians diagnose and treat food intolerances. Unlike traditional methods that rely on trial and error or tests with high false-positive rates¹, this innovative approach uses real-time cellular imaging to observe how a patient’s body reacts to specific foods at the microscopic level.

The Hidden Epidemic

Irritable Bowel Syndrome affects an estimated 12% of the U.S. population², and research shows that more than half of these patients experience symptoms related to food intolerance.³ Yet despite the prevalence of this condition, many sufferers struggle for years without identifying the root cause of their discomfort. The impact extends far beyond occasional stomach upset. One study revealed that 40% of people with digestive symptoms have stopped routine activities such as running errands, exercising, and socializing because of uncomfortable bowel symptoms.⁴ The professional and economic toll is equally significant, with 36% of affected individuals missing work, 17% seeking medical care, and 15% requiring hospitalization.⁵

The challenge lies partly in the nature of food intolerances themselves. Unlike traditional food allergies, which trigger immediate and sometimes life-threatening immune responses, food intolerances develop when the body cannot properly process or break down specific foods or the gut’s immune system reacts inappropriately to the food. The resulting symptoms are primarily gastrointestinal, including heartburn, nausea, cramping, bloating, and/or diarrhea, though they can also manifest as migraine headaches, itchy skin, nasal congestion, and joint pain. These non-life-threatening but quality-of-life-destroying symptoms often mimic other conditions, making accurate diagnosis particularly difficult.

The Limitations of Current Testing Methods

Traditional approaches to diagnosing food intolerances have significant drawbacks. Beyond specific carbohydrate intolerances (lactose, sucrose, fructose) and celiac disease, for which testing exists, physicians typically resort to empiric exclusion diets or restrictive eating plans like the low-FODMAP diet. While these approaches can provide relief for some patients, they are far from perfect solutions.

Elimination diets require patients to systematically remove potential trigger foods from their diet, then slowly reintroduce them one at a time while monitoring symptoms. This process can take months and requires meticulous record-keeping and patience. Many patients abandon these diets before completing them, and even when followed correctly, results can be ambiguous.

The low-FODMAP diet, which restricts fermentable carbohydrates, has gained popularity as a management strategy for IBS. However, these diets are intended for short-term use only and are not permanent solutions. They can be highly restrictive, nutritionally complex, burdensome for patient compliance, and costly, often requiring multiple sessions with a dietitian. Other testing methods have their own limitations. Blood tests and skin prick tests yield false positive results in 50% to 60% of cases¹, leading patients down unnecessary dietary restriction paths. The accuracy of hydrogen breath tests remains unclear for IBS patients. Perhaps most tellingly, only half of patients with IBS receive a definitive diagnosis after seeing a physician⁶, and 37% find that current tests and elimination diets do not lead to a clear treatment pathway.⁷

How CellTolerance Works

The CellTolerance test takes a fundamentally different approach by directly observing the interaction between food and the gastrointestinal tract in real time. The procedure is performed during a routine upper endoscopy that takes approximately 20 to 25 minutes, with patients receiving the same sedation they would for a standard endoscopy.

During the procedure, physicians spray food agents or allergens onto the duodenal mucosa, a specialized layer of tissue within the initial segment of the small intestine, through the working channel of the endoscopy scope. They then use the Cellvizio flexible confocal laser endomicroscopy probe to visualize and identify impaired epithelial barrier function in response to those food agents as they happen.

This test is powered by Cellvizio, the only multidisciplinary probe and needle-based confocal laser endomicroscopy platform that enables such direct, real-time observation. The system uses advanced imaging to enable precision medicine and diagnostic accuracy, allowing physicians to see exactly which foods trigger problematic reactions at the cellular level.

Up to five foods can be tested during a single procedure, allowing doctors to identify precisely which items are causing the patient’s symptoms. The technology can also identify patients with primary barrier dysfunction, sometimes called “leaky gut,” providing additional diagnostic insights that can guide treatment.

Who Should Consider the Test & Proven Results

The CellTolerance test is designed for specific patient populations who have struggled with conventional diagnostic approaches. Ideal candidates include patients with suspected IBS and food-related triggers, those experiencing food-related IBS-like symptoms, individuals who have tried elimination diets without success, and those experiencing persistent gastrointestinal symptoms without a clear diagnosis.

The clinical outcomes associated with CellTolerance distinguish it from traditional diagnostic approaches. Current data demonstrates that 96% of patients who test positive and follow their CellTolerance-guided diet experience symptom improvement within six months³. This remarkably high success rate reflects the precision of the diagnosis and the effectiveness of personalized dietary interventions based on direct observation of cellular responses.

Across several studies, an average of nearly 70% of CellTolerance patients were diagnosed with and treated for food-induced intestinal barrier impairment³, a condition that might otherwise have gone unrecognized and untreated. In a prospective interventional study that compared CellTolerance to other approaches, researchers included a healthy control group and randomly assigned participants to either a low-FODMAP diet, a food exclusion diet identified by confocal laser endomicroscopy, or a placebo diet. The results were striking: 41 out of 42 CLE-positive patients showed an improvement of symptoms of more than 70% following a food exclusion diet based on their test results.⁸

The study supports the critical role played by atypical allergies in food-sensitive IBS patients and highlights the technology’s capacity to detect them. Symptom scores were better with the CLE-guided food exclusion diet than with the low-FODMAP diet, and anxiety and somatization scores improved significantly with CLE-guided dietary intervention.⁸ This psychological benefit is noteworthy, as the uncertainty and unpredictability of undiagnosed food intolerances often contribute to anxiety and stress. The test successfully identified specific food agents, including wheat, yeast, soy, milk, and gluten, as triggers, enabling precise, personalized diets rather than broadly restrictive eating plans.

Transforming Patient Outcomes

The CellTolerance test provides concrete visual evidence of the body’s reaction to specific foods, ending years of uncertainty for patients who have struggled with unclear diagnoses. After receiving test results and implementing a personalized dietary plan, patients report dramatic improvements not only in physical symptoms but also in overall quality of life. Professional performance improves, social relationships strengthen, and the anxiety associated with unpredictable symptoms diminishes. CellTolerance allows GIs to transition patients from broad, restrictive diets to evidence-based, targeted exclusion, significantly improving long-term compliance and quality of life.

The technology’s high success rate stems from its ability to observe biological reality in real time rather than relying on indirect measurements. Traditional testing depends on identifying antibodies or observing delayed reactions, methods prone to errors because they measure proxy indicators. Confocal laser endomicroscopy provides direct visualization of cellular responses as they occur, eliminating guesswork and providing immediate, objective results.

Broader Healthcare Impact

The CellTolerance test offers benefits that extend beyond individual patient outcomes. By providing accurate diagnoses in a single procedure, the technology can reduce healthcare costs and resource utilization. The underlying Cellvizio platform has been used in more than 100,000 patient procedures worldwide and has been featured in more than 1,200 clinical papers. It has received over 20 FDA clearances, CE mark certification, and dedicated category 1 CPT Codes. Cellvizio use has been associated with high patient satisfaction scores and lower healthcare services utilization across multiple areas, including reduced endoscopy procedures, decreased anesthesia requirements, and fewer biopsies needed. For patients with food intolerances, this translates to a more streamlined diagnostic journey with fewer repeat procedures and faster time to effective treatment.

The Path Forward

For millions of Americans living with undiagnosed food intolerances, CellTolerance offers hope for definitive answers and lasting relief. By replacing months or years of trial-and-error dieting with a single diagnostic procedure, this technology transforms how physicians approach these challenging conditions.

Whether patients test positive or negative to specific foods, they receive personalized dietary plans based on their specific cellular responses, enabling informed nutrition decisions without unnecessary restrictions. This precision approach improves physical symptoms while addressing the psychological burden of living with an undiagnosed condition.

As more health systems adopt CellTolerance, access to this breakthrough will expand. The technology’s use in pediatric settings is particularly promising, preventing years of suffering in children and potential developmental impacts. Its integration into gastroenterological practice represents a broader shift toward precision medicine in digestive health, offering targeted, evidence-based interventions tailored to individual physiology rather than generic dietary restrictions.

For those who have searched for answers while their quality of life suffered, CellTolerance provides the end of uncertainty and the beginning of effective, personalized treatment that validates their experiences and improves outcomes. The future of food intolerance diagnosis is visible at the cellular level.

References

1. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Jonsson JS, Bjornsson E, Thjodleifsson B. Irritable bowel syndrome: physicians’ awareness and patients’ experience. World journal of gastroenterology. 2012; 18(28), 3715–3720. doi:10.3748/wjg.v18.i28.3715.
2. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015 Mar 3;313(9):949-58. doi: 10.1001/jama.2015.0954
3. Fritscher-Ravens A, Pflaum T, Mösinger et al. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. Gastroenterology. 2019 Jul;157(1):109-118.
4. https://gastro.org/press-releases/new-survey-finds-forty-percent-of-americans-daily-lives-are-disrupted-by-digestive-troubles/ Accessed February 2026.
5. Quigley, E. M., Horn, J., Kissous-Hunt, M., Crozier, R. A., & Harris, L. A. (2018). Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. Journal of Clinical Medicine, 7(7), 176. https://doi.org/10.3390/jcm7070176
6. Halpert A. Review Irritable Bowel Syndrome: Patient-Provider Interaction and Patient Education. J. Clin. Med. 2018, 7(1), 3. doi: 10.3390/jcm7010003.
7. YouGOV Survey executed by Mauna Kea Technologies, March 2024

8. Fritscher-Ravens, Annette & Ruchay, Zino & Pflaum, Theresa & Moesinger, Marie & Schuppan, Detlef. (2020). 623 EXCLUSION OF ATYPICAL FOOD ALLERGENS DETECTED BY CONFOCAL ENDOMICROSCOPY IS SUPERIOR TO A LOW FODMAP DIET IN PATIENTS WITH FOOD-SENSITIVE IBS. Gastroenterology. 158. S-135. 10.1016/S0016-5085(20)31016-7.

Editor’s note: Linda Nguyen, MD, FACG, AGAF, is Division Chief, Gastroenterology & Hepatology for the Hoag Digestive Health Institute and Clinical Professor of Medicine at Stanford University. Her clinical and research interests include GI motility disorders and disorders of gut-brain interaction, with an emphasis on gastroparesis, functional dyspepsia, and chronic abdominal pain.

Daryl Donatelli, MBA is President, U.S. & Head of Global Marketing for Mauna Kea Technologies, where he leads the strategic direction and operational execution of the U.S. business for Cellvizio, the real-time, in vivo cellular imaging platform, and CellTolerance, a test designed to quickly identify and manage food intolerances for patients.